Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Brooks Laboratories Ltd Performance

Today's Low
98.95
arrowIcon
Today's High
98.95
52 Wk Low
56.95
arrowIcon
52 Wk High
185.70


Open

98.95

Traded Value (Cr)

3.20 L

Prev. Close

100.95

VWAP

101.35

Volume

9,827

Face Value

10

Brooks Laboratories Ltd Fundamentals

Market Cap
₹ 266 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
3.37
Debt to Equity
0.05
ROE
-19.50 %
EPS (TTM)
0.00
Dividend Yield
0.00%
Book Value
30.14

Click here to know more about Fundamentals

Brooks Laboratories Ltd Financials

Brooks Laboratories Ltd Financials

Brooks Laboratories Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Aug 2023
Promoters 63.59 % 63.59 % 63.59 % 63.59 %
Retail 25.55 % 25.21 % 26.89 % 27.80 %
Others 7.00 % 7.33 % 7.06 % 7.36 %
Mutual Funds 3.86 % 3.86 % 2.46 % 1.25 %
FII 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

63.59%

Retail

25.55%

Others

7.00%

Mutual Funds

3.86%

FII

0.00%

Promoters

63.59%

Retail

25.21%

Others

7.33%

Mutual Funds

3.86%

FII

0.00%

Promoters

63.59%

Retail

26.89%

Others

7.06%

Mutual Funds

2.46%

FII

0.00%

Promoters

63.59%

Retail

27.80%

Others

7.36%

Mutual Funds

1.25%

FII

0.00%

Resistance and Support

₹0.00

PIVOT

resistance-arrow
Resistance
First Resistance₹0.000
Second Resistance₹0.000
Third Resistance₹0.000
support-arrow
Support
First Resistance₹0.000
Second Resistance₹0.000
Third Resistance₹0.000
RSI51.881
MACD-1.053
ADX12.869
CCI-52.068

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day9,8279,827100.00
Week9,7639,763100.00
1 Month17,07417,074100.00
6 Months24,90524,905100.00

About Brooks Laboratories Ltd

Brooks Laboratories Ltd is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi, Himachal Pradesh and Vadodara, Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables, 19 Tablets and 2 Dry Syrups which are marketed domestically. The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India. The company's major clients are companies like Zydus Cadila, Aristo Pharmaceuticals Pvt Ltd, FDC Ltd, Nectar Lifesciences Ltd, Sanat Products Ltd, Hetero Healthcare Ltd, Medley Pharmaceuticals, Wockhardt Ltd, Parental Drugs, Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd, Aurobindo Pharma Ltd, DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd. Brooks Laboratories Ltd was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers. In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (R&D) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production. In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal & Rajesh Mahajan. In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF. In August 2011, Brooks Laboratories raised Rs. 63 crore from the public through IPO. The shares of the company got listed on the stock exchanges with effect from 5 September 2011. During the financial year ended 31 March 2014, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016, the company operated the Baddi plant at 92% capacity. On 7 March 2017, Brooks Laboratories' world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit, the company decided to upgrade the Baddi facility in steps. As a first step, the company upgraded one injectable manufacturing line, which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review. The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017, whereby production in injectable line was affected, upgradation was completed and production started from September onwards in Baddi facility. During the year ended 31 March 2018, the company operated the Baddi plant at 90% capacity except for 3 months from June to August due to upgradation of injectable facility in Baddi. The company commenced production in August 2017 in new renovated building at Baddi plant with almost double the capacity of previous line.

Managing Director

Founded

2002

NSE Symbol

BROOKS

Brooks Laboratories Ltd Management

NameDesignation
Rajnish Kumar BediIndependent Director
Deepak MahajanIndependent Director
Sonia GuptaIndependent Director
Jitendra Pratap SinghWhole Time Director
Durga Sankar MaityWhole-time Director
Mr. Bhushan Singh RanaWhole-time Director
JAI PRAKASH VAIDYACompany Sec. & Compli. Officer

Brooks Laboratories Ltd News

Brooks Laboratories reports consolidated net loss of Rs 3.88 crore in the December 2023 quarter
Sales rise 42.16% to Rs 21.75 crore
Brooks Laboratories to hold board meeting
On 31 January 2024
Brooks Laboratories to convene board meeting
On 24 January 2024
Brooks Laboratories Ltd leads gainers in 'B' group
Meera Industries Ltd, Kothari Products Ltd, Inventure Growth & Securities Ltd and Almondz Global Securities Ltd are among the other gainers in the BSE's 'B' group today, 04 January 2024.
Brooks Laboratories reports consolidated net loss of Rs 1.64 crore in the September 2023 quarter
Sales rise 34.51% to Rs 24.32 crore
Brooks Laboratories to discuss results
On 9 November 2023
Brooks Laboratories to hold AGM
On 21 September 2023
Brooks Laboratories reports consolidated net loss of Rs 4.47 crore in the June 2023 quarter
Sales decline 8.29% to Rs 15.70 crore
Brooks Laboratories to declare Quarterly Result
On 10 August 2023
Brooks Laboratories to convene board meeting
On 11 July 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,58,616 Cr
₹ 1,506.55
(0.80 %)
86.97
CIPLA₹ 1,09,708 Cr
₹ 1,339.55
(-1.42 %)
33.36
DIVISLAB₹ 1,00,611 Cr
₹ 3,793.50
(0.09 %)
73.75
DRREDDY₹ 98,044 Cr
₹ 5,921.00
(0.74 %)
22.59
ZYDUSLIFE₹ 97,423 Cr
₹ 982.15
(1.44 %)
36.23

Brooks Laboratories Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Brooks Laboratories Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Brooks Laboratories Ltd's share price is ₹98.95 as of May 10, 2024

Brooks Laboratories Ltd's P/E ratio is 0.00 times as of May 10, 2024.

Brooks Laboratories Ltd's most recent financial reports indicate a price-to-book ratio of 3.37, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Brooks Laboratories Ltd's market is 267 Cr as on May 10, 2024.

The current financial records of Brooks Laboratories Ltd show a -19.50% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Brooks Laboratories Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Brooks Laboratories Ltd's 52-week high and low as of May 10, 2024 are ₹98.95 and ₹98.95 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Brooks Laboratories Ltd stands at 63.59%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 0.00% to 0.00%.